Results 31 to 40 of about 9,194 (267)

Radium-223 dichloride: a new paradigm in the treatment of prostate cancer [PDF]

, 2015
Review[Abstract] Radionuclides have been widely used for cancer treatment. Recently, new research about radium-223 dichloride has been conducted in prostate cancer, which reveals that it is the first radiopharmaceutical to demonstrate an improvement in ...
Afonso Afonso, Francisco Javier, Anido Herranz, Urbano, Antón-Aparicio, Luis M., Fernández Calvo, Ovidio, León Mateos, Luis, Lázaro Quintela, Martín, Rodríguez Martínez de Llano, Sofía, Vázquez Estévez, Sergio   +7 more
core   +2 more sources

Advances in targeted Alpha therapy for prostate cancer [PDF]

, 2019
BACKGROUND: Amongst therapeutic radiopharmaceuticals, targeted alpha therapy (TαT) can deliver potent and local radiation selectively to cancer cells as well as the tumor microenvironment and thereby control cancer while minimizing toxicity.
De Vincentis, G, Gerritsen, W, Gschwend, JE, Hacker, M, Lewington, V, O'Sullivan, JM, Oya, M, Pacilio, M, Parker, C, Sartor, O, Shore, N, Targeted Alpha Therapy Prostate Working Group   +11 more
core   +2 more sources

Circulating tumor cells and γH2AX as biomarkers for responsiveness to radium-223 in advanced prostate cancer patients

Future Science OA, 2020
Aim: Radium-223 improves overall survival in patients with metastatic castration-resistant prostate cancer to the bone. Radium-223 causes double-strand DNA breaks and produces γH2AX, a potential biomarker for response.
Jonathan Chatzkel, Jesse Mocha, Johnna Smith, Jun-Min Zhou, Youngchul Kim, Ghassan El-Haddad, Jingsong Zhang   +6 more
doaj   +1 more source

Pain outcomes in patients with bone metastases from advanced cancer: assessment and management with bone-targeting agents [PDF]

, 2014
Bone metastases in advanced cancer frequently cause painful complications that impair patient physical activity and negatively affect quality of life. Pain is often underreported and poorly managed in these patients.
A Kretzschmar, A Mañas, A Wardley, AT Stopeck, C Langer, C Logothetis, Charles S. Cleeland, CI Ripamonti, CJ Logothetis, CS Cleeland, CS Cleeland, D Henry, D Patrick, DH Henry, DL Patrick, Donald L. Patrick, DS Ernst, E Basch, E Chow, F Saad, F Saad, G Apolone, G Cartenì, G Storto, GN Hortobagyi, GN Hortobagyi, HI Scher, JJ Body, JJ Body, K Altundag, K Fizazi, K Harris, Katarina Öhrling, KC Chung, KP Weinfurt, KP Weinfurt, L Atahan, L Costa, L Fallowfield, Lesley Fallowfield, LS Matza, LS Rosen, LS Rosen, LS Rosen, M Huisman, M Martin, M Tomblyn, MG Lam, MJ Fisch, N Kohno, N Takeda, P Hoskin, P Hoskin, R Moos von, R Moos von, Rachel Wei, RE Coleman, RE Coleman, RE Coleman, RH Dworkin, RL Theriault, Roger von Moos, S Deandrea, S Nilsson, S Vadhan-Raj, SD Mathias, T Kijima, V Vassiliou, V Vassiliou, Yi Qian   +69 more
core   +1 more source

A phase II randomized trial of metastasis-directed therapy with alpha emitter radium-223 in men with oligometastatic castration-resistant prostate cancer (MEDAL)

BMC Urology, 2023
Background The significance of metastasis-directed therapy for oligometastatic prostate cancer has been widely discussed, and targeted therapy for progressive sites is a feasible option as a multidisciplinary treatment for castration-resistant prostate ...
Soichiro Yoshida, Taro Takahara, Yuki Arita, Masaya Ito, Sara Hayakawa, Tomohiko Oguchi, Yoshinobu Komai, Noboru Numao, Takeshi Yuasa, Masaharu Inoue, Hiroki Ushijima, Shigehiro Kudo, Yasumasa Shimano, Yuki Nakamura, Yusuke Uchida, Sho Uehara, Hajime Tanaka, Hiroshi Yaegashi, Kouji Izumi, Minato Yokoyama, Yoh Matsuoka, Yasuo Yoshioka, Koji Konishi, Katsuyuki Nakanishi, Akira Nagahara, Akihiro Hirakawa, Ryuji Koike, Fumitaka Koga, Kazuo Nishimura, Atsushi Mizokami, Junji Yonese, Yukio Kageyama, Ryoichi Yoshimura, Yasuhisa Fujii   +33 more
doaj   +1 more source

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer

Frontiers in Oncology, 2021
BackgroundRadium-223 improves overall survival (OS) in men with bone metastatic castration-resistant prostate cancer (mCRPC). While the exact mechanism behind this survival benefit remains unclear, radium-induced immunological mechanisms might contribute
Jeroen H. A. Creemers, Jeroen H. A. Creemers, Maarten J. van der Doelen, Maarten J. van der Doelen, Sandra van Wilpe, Sandra van Wilpe, Rick Hermsen, Tjitske Duiveman-de Boer, Diederik M. Somford, Marcel J. R. Janssen, J. P. Michiel Sedelaar, Niven Mehra, Niven Mehra, Johannes Textor, Johannes Textor, Harm Westdorp, Harm Westdorp   +16 more
doaj   +1 more source

Real-world outcomes of sipuleucel-T treatment in PROCEED, a prospective registry of men with metastatic castration-resistant prostate cancer. [PDF]

, 2019
BackgroundThe large registry, PROVENGE Registry for the Observation, Collection, and Evaluation of Experience Data (PROCEED)(NCT01306890), evaluated sipuleucel-T immunotherapy for asymptomatic/minimally symptomatic metastatic castration-resistant ...
Armstrong, Andrew J, Chang, Nancy N, Concepcion, Raoul S, Cooperberg, Matthew R, Harmon, Matt, Higano, Celestia S, Kantoff, Philip W, Kassabian, Vahan, McLeod, David G, Nordquist, Luke T, Penson, David F, Pieczonka, Christopher M, Quinn, David I, Sartor, A Oliver, Scholz, Mark C, Shore, Neal D, Tang, Hong, Tutrone, Ronald F, Tyler, Robert C, Vacirca, Jeffrey, Vogelzang, Nicholas J   +20 more
core   +2 more sources

The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of prostate carcinoma. [PDF]

, 2016
Prostate cancer is the most commonly diagnosed malignancy and second leading cause of cancer death among men in the United States. In recent years, several new agents, including cancer immunotherapies, have been approved or are currently being ...
Bander, Neil H, Beer, Tomasz M, Drake, Charles G, Fong, Lawrence, Gulley, James L, Harrelson, Stacey, Kantoff, Philip W, Madan, Ravi A, McNeel, Douglas G, Oh, William K, Peace, David J, Petrylak, Daniel P, Porterfield, Hank, Sartor, Oliver, Shore, Neal D, Slovin, Susan F, Stein, Mark N, Vieweg, Johannes   +17 more
core   +1 more source

A real-world evaluation of radium-223 in combination with abiraterone or enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

PLoS ONE, 2021
IntroductionRadium-223, abiraterone, and enzalutamide have each been shown to significantly improve survival as monotherapy in patients with metastatic castration-resistant prostate cancer.
Stephanie I Kim, Andy H Szeto, Katherine P Morgan, Blaine Brower, Mary W Dunn, Amir H Khandani, Paul A Godley, Tracy L Rose, Ethan M Basch, Matthew I Milowsky, Young E Whang, Daniel J Crona   +11 more
doaj   +1 more source

Radium-223 dichloride treatment in metastatic castration-resistant prostate cancer in Finland: A real-world evidence multicenter study [PDF]

, 2022
Prostate cancer is the second most commonly diagnosed cancer type and the sixth leading cause of cancer-related death among men worldwide. The prognosis for localized prostate cancer is good, with 5-year survival rates over 90%.
Hyväkkä, Anniina
core